Plain-English translation of NCT06920628 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This research study is investigating whether people with long COVID who experience neurological symptoms have increased inflammation in their brains. Researchers will use a special type of brain imaging called PET scanning to look for a marker of inflammation called COX-1. The study will also test whether a treatment called intravenous immunoglobulin (IVIg) — which contains antibodies to help regulate the immune system — can reduce this inflammation and improve symptoms.
Long COVID can cause serious brain-related symptoms like cognitive problems and movement difficulties, but we don't yet understand what causes these symptoms or how to treat them effectively. This study aims to identify a biological marker of brain inflammation that could help explain why some people have these symptoms and whether immune-based treatment can help.
You likely qualify if…
You likely don't qualify if…
You will come to the National Institute of Mental Health for PET brain imaging scans, which are special pictures that show activity in your brain. You may also receive the immune therapy treatment (IVIg) and have a second scan afterward to see if the treatment affects the inflammation marker. The study involves blood tests, a finger-tapping coordination test, and other standard medical evaluations. The exact duration and number of visits will be explained during your screening, but you should expect multiple appointments over several weeks.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States